Gyawali Bishal, Ramakrishna Karan, Dhamoon Amit S
Department of Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.
SAGE Open Med. 2019 Mar 21;7:2050312119835043. doi: 10.1177/2050312119835043. eCollection 2019.
There has been a significant evolution in the definition and management of sepsis over the last three decades. This is driven in part due to the advances made in our understanding of its pathophysiology. There is evidence to show that the manifestations of sepsis can no longer be attributed only to the infectious agent and the immune response it engenders, but also to significant alterations in coagulation, immunosuppression, and organ dysfunction. A revolutionary change in the way we manage sepsis has been the adoption of early goal-directed therapy. This involves the early identification of at-risk patients and prompt treatment with antibiotics, hemodynamic optimization, and appropriate supportive care. This has contributed significantly to the overall improved outcomes with sepsis. Investigation into clinically relevant biomarkers of sepsis are ongoing and have yet to yield effective results. Scoring systems such as the sequential organ failure assessment and Acute Physiology and Chronic Health Evaluation help risk-stratify patients with sepsis. Advances in precision medicine techniques and the development of targeted therapy directed at limiting the excesses of the inflammatory and coagulatory cascades offer potentially viable avenues for future research. This review summarizes the progress made in the diagnosis and management of sepsis over the past two decades and examines promising avenues for future research.
在过去三十年里,脓毒症的定义和管理发生了重大演变。部分原因是我们对其病理生理学的理解取得了进展。有证据表明,脓毒症的表现不再仅归因于感染因子及其引发的免疫反应,还归因于凝血、免疫抑制和器官功能障碍的显著改变。我们管理脓毒症方式的一个革命性变化是采用早期目标导向治疗。这包括早期识别高危患者,并迅速使用抗生素治疗、进行血流动力学优化以及给予适当的支持性护理。这对脓毒症总体预后的改善做出了重大贡献。对脓毒症临床相关生物标志物的研究正在进行,但尚未产生有效结果。序贯器官衰竭评估和急性生理与慢性健康评估等评分系统有助于对脓毒症患者进行风险分层。精准医学技术的进步以及旨在限制炎症和凝血级联反应过度的靶向治疗的发展为未来研究提供了潜在可行的途径。本综述总结了过去二十年脓毒症诊断和管理方面取得的进展,并探讨了未来研究的有前景的途径。